BETA
Your AI-Trained Oncology Knowledge Connection!
Real-World Data Show Activity With Ivosidenib in IDH1+ Cholangiocarcinoma
Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
Characterizing Tumor Cell Diversity with AI
“Developments that take high-dimensional data and come up with interpretable insights…are going to play an increasing role,” says Smita Krishnaswamy, PhD.
Enzalutamide Prolongs Survival in nmHSPC With Biochemical Recurrence
More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.
Tislelizumab/Chemotherapy Earns EU Approval in Nasopharyngeal Carcinoma
Data from the RATIONALE-309 trial support the European Commission’s approval of frontline tislelizumab plus chemotherapy in this patient population.
Tarlatamab Shows Promising Real-World Activity in Extensive-Stage SCLC
Treatment with tarlatamab demonstrated intracranial responses in a real-world cohort of patients with extensive-stage small cell lung cancer.
HTMC0435 Plus Chemotherapy Yields Responses in Relapsed ES-SCLC
HTMC0435 plus temozolomide led to an ORR of 24.5%, with a median OS of 12.0 months, in patients with platinum-sensitive and platinum-resistant small cell lung cancer.
Denosumab Biosimilars Available in the US for Bone Mets, Multiple Myeloma
The 2 denosumab biosimilars previously received FDA approval for select patients with multiple myeloma, solid tumor bone metastases, and osteoporosis.
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
Pembrolizumab/Vorinostat Has Promising Activity in Squamous Cell Carcinoma
Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.
FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML
A PDUFA date for decitabine/cedazuridine and venetoclax in newly diagnosed AML has been set for February 25, 2026.
Pexidartinib Elicits Sustained Benefit in Tenosynovial Giant Cell Tumors
Final data from the phase 3 ENLIVEN trial demonstrate long-term tumor responses and a consistent safety profile with pexidartinib.
Botensilimab/Balstilimab Elicits Sustained Efficacy in MSS Metastatic CRC
The FDA has waived the need for a botensilimab monotherapy arm in the phase 3 BATTMAN trial evaluating the combination in MSS metastatic colorectal cancer.
Tislelizumab Combo Improves Outcomes in Locally Advanced ESCC Subgroups
Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.
Novel Trispecific Antibody May Offer “Renewed Hope” in R/R Multiple Myeloma
Treatment with ISB 2001 demonstrated robust responses across difficult-to-treat multiple myeloma subgroups in the phase 1 TRIgnite-1 study.
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
Anti-Angiogenesis Plus ICIs, Chemo Improve Frontline Efficacy in ES-SCLC
The addition of angiogenesis inhibition to immunochemotherapy for untreated extensive-stage small cell lung cancer did not significantly increase toxicity.
ASCT Shows No Significant MRD− Difference Vs Isa-KRd in Multiple Myeloma
Longer follow-up from the phase 3 MIDAS trial may be necessary to evaluate progression-free survival and overall survival.
FDA Grants Orphan Drug Designation to ADRX-0405 for Gastric Cancer
Results from the phase 1a/b trial evaluating ADRX-0405 in various solid tumors, including gastric cancer, are expected to come in late 2025.
ZL-1310 Shows Promising Activity in Pretreated R/R ES-SCLC
Data from a phase 1 trial showed an ORR of 68% and a DCR of 93% with ZL-1310 in those with extensive-stage small cell lung cancer during dose escalation.
Encorafenib Combo Yields Efficacy Across BRAF V600E+ CRC Subgroups
Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.
FDA Grants Orphan Drug Designation to FF-10832 in Biliary Tract Cancer
The liposomal formulation of gemcitabine may enhance anti-tumor activity by increasing plasma half-life and improving targeted delivery to tumors.
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
Olanzapine Combo Reduces Chemo-Induced Nausea, Vomiting in Breast Cancer
Patient-reported satisfaction was higher in patients with breast cancer treated with olanzapine vs those who underwent treatment with placebo.
HAIC Regimen Yields Long-Term Survival in Unresectable HCC
HAIC with oxaliplatin and raltitrexed produced a higher response rate vs other systemic therapy agents in patients with advanced hepatocellular carcinoma.
Bria-IMT Yields Updated Survival Benefit in Metastatic Breast Cancer
Survival benefit was observed in heavily pretreated populations, including those who progressed after checkpoint inhibition and antibody-drug conjugates.
Teclistamab Shows Viability in Anti-BCMA–Pretreated Multiple Myeloma
Prior BCMA-DT exposure was associated with a trend toward worse PFS outcomes and a lower likelihood of response in patients with multiple myeloma.
Advancing Treatment for EGFR Inhibitor–Associated Dermal Toxicities
ATR04-484 showed inhibition of both methicillin-sensitive and methicillin-resistant Staphylococcus aureus bacteria strains, which are associated with rash.
IDH Triplet Therapy Shows Excellent Outcomes in IDH-Mutant AML
Current data support prospective studies comparing IDH triplet vs IDH doublet therapies among patients with IDH-mutant acute myeloid leukemia.
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study